Naxitamab is a GD2-targeted IgG1 monoclonal antibody for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow. Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.
- Mechanism
- Curator reviewed · 5 references
Neuroblastomas are neuroendocrine tumors occurring in immature and developing cells of the nervous system and are the most common malignancy diagnosed in children <1 year of age. The GD2 disialoganglioside is a glycolipid found highly expressed on the surface of neuroectodermal tumors, including neuroblastomas. GD2 exhibits high density and homogeneity across neuroblastomas and a rare occurrence of antigen loss, making it a desirable target in the treatment of these cancers.
Naxitamab is an IgG1 monoclonal antibody directed against GD2 disialogangliosides - it binds to GD2 on the surface of neuroblastoma cells and induces both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), the latter of which is enhanced by co-administration with GM-CSF.
- Primary indication
- Naxitamab-gqgk is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of patients 1 year of age and older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have...Curator reviewed · 4 structured indications
- Formula / weight
- 144000.0 Da (non-glycosylated)
- First approval
- United States, 2020
- Also known as
- Anti-Gd2 igg3 monoclonal antibody 3F8 humanized · Anti-Gd2 monoclonal antibody 3F8 humanized · HU3F8 · Humanized 3F8 · Humanized anti-Gd2 monoclonal antibody 3F8
- Brand names
Resolves to
What you can answer from here — as of March 06, 2025
Which other approved drugs treat the same conditions as Naxitamab, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account